SOLIGENIX, INC. — Director's Dealing 2008

Dec 19, 2008

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2008-12-18

Reporting Person: MYRIANTHOPOULOS EVAN (Director, Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2008-12-18	Stock Options (Right to Buy)	$0.06	A	1200000	Acquired	2018-12-17	Common Stock (1200000)	Direct

Footnotes

F1: The stock options were granted at an exercise price of $0.06. The stock options, which are for a term of 10 years from the date of grant and subject to earlier termination upon the occurence of certain events related to termiatnion of employment, vest at a rate of 25% immediately and 25% per year for 3 years.